Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

Trial StartSKB565Positive

AI Analysis

Summary

Sichuan Kelun-Biotech announced it received a clinical trial notice from China's Center for Drug Evaluation for SKB565, its first dual-payload antibody-drug conjugate. The approval enables the company to initiate clinical development of the candidate.

Clinical Trial Data

Outcome Details

Clinical trial notice received from CDE

Importance:5/10

Sentiment:

0.60

ADCdual-payloadclinical trialChinaCDE approval

Related Companies

$SKBBY

Read the original article

Published by PR Newswire Biotech on July 27, 2026 11:30 AM

Read Original